AI Terminal
Eckert & Ziegler Strahlen- und Medizintechnik AG
Regulatory Filings • Aug 26, 2021
130_rns_2021-08-26_c042704a-8dc5-4c3f-bf3c-64b1e92d0b80.html
Regulatory Filings
Open in ViewerOpens in native device viewer
News Details
Corporate | 26 August 2021 10:20
Eckert & Ziegler Starts Technetium-99 Delivery in Brazil
DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Miscellaneous
26.08.2021 / 10:20
The issuer is solely responsible for the content of this announcement.
Berlin, 26 August 2021. Eckert & Ziegler (ISIN DE0005659700, TecDAX), has started the delivery of Technetium-99 generators in Brazil. The subsidiary Eckert & Ziegler Brasil Comercial Ltda. had recently received a license from the Brazilian health authority ANVISA as the first and only private company to import and distribute technetium generators. Two leading hospitals in the greater Sao Paulo area are among the first customers, and further orders have already been placed.
Technetium generators are a core component for a nuclear medicine diagnostic procedure called SPECT, which is used to detect medical abnormalities. The generators need to be replaced regularly because the radioactive material in them has a short half-life. In Brazil, the SPECT market has a volume of about 100 million Euro per year. Eckert & Ziegler already supplies around 500 hospitals and clinics in this country with medical products and radioisotopes and now hopes to tap into the generator market. SPECT is often used to detect cardiac diseases, tumors, and metastases.
About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 800 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.
Your contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, [email protected] , www.ezag.com
26.08.2021 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
| Language: | English |
| Company: | Eckert & Ziegler Strahlen- und Medizintechnik AG |
| Robert-Rössle-Str.10 | |
| 13125 Berlin | |
| Germany | |
| Phone: | +49 30 941084-138 |
| Fax: | +49 30 941084-112 |
| E-mail: | [email protected] |
| Internet: | www.ezag.de |
| ISIN: | DE0005659700 |
| WKN: | 565970 |
| Indices: | SDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1229044 |
| End of News | DGAP News Service |